文献速递腹部MR

ANALI评分在原发性硬化性胆管炎中的预后价值与阅片者间一致性评估

Assessment of prognostic value and interreader agreement of ANALI scores in patients with primary sclerosing cholangitis.
PubMed 文献 · Eur J Radiol · 2021-07-31

本研究基于98例原发性硬化性胆管炎患者的前瞻性队列,由三位放射科医生评估MRI并计算两种ANALI评分,评估阅片者间一致性及预后价值。结果显示无钆评分一致性差至中等(ICC=0.56),含钆评分一致性差(ICC=0.30),但两评分均与临床结局相关,肝相关死亡、移植或肝硬化失代偿的风险比分别为2.25和3.53。

要点

  • 含钆ANALI评分阅片者间一致性差(ICC=0.30),临床使用需谨慎。
  • 肝变形和实质强化不均匀的一致性差(ICC分别为0.28和0.24)。
  • 无钆和有钆ANALI评分均与临床结局相关,支持影像预后价值。

诊断标准与关键数值

  • 无钆ANALI评分ICC=0.56(95%CI: 0.42-0.68),含钆ANALI评分ICC=0.30(95%CI: 0.16-0.44)。
  • 肝变形ICC=0.28(95%CI: 0.13-0.44),实质强化不均匀ICC=0.24(95%CI: 0.12-0.38)。
  • 门静脉高压ICC=0.48(95%CI: 0.36-0.59),肝内胆管扩张ICC=0.64(95%CI: 0.54-0.73)。
  • 含钆和无钆ANALI评分预测肝相关死亡、移植或肝硬化失代偿的风险比分别为3.53(95%CI: 1.40-8.93)和2.25(95%CI: 1.56-3.24)。

临床应用与阅片要点

  • 使用ANALI评分时需注意肝变形和实质强化不均匀的主观性导致一致性低。
  • 无钆ANALI评分一致性较好且预后价值明确,可优先考虑。
  • 低ANALI评分患者无结局生存率更好,可用于风险分层。

局限性

  • 单中心研究,需多中心验证。
  • 样本量98例,随访6.7年,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: ANALI-scores are two prognostic magnetic resonance imaging (MRI)-based scores developed for patients with primary sclerosing cholangitis (PSC). Our study aims to assess the interreader agreement between expert radiologists of the two ANALI-scores and of the radiological parameters they utilize, and to test the prognostic performance of the scores in our population.

METHOD: Three radiologists evaluated MRIs of 98 PSC-patients from a prospectively collected cohort with median follow-up of 6.7 years. Each parameter of ANALI-scores was assessed, and the scores were calculated. Interreader agreement was assessed with intraclass correlation coefficient (ICC). After consensus reading was reached, the prognostic value of ANALI-scores was assessed with Cox regression, and outcome-free survival rates were evaluated with Kaplan-Meier estimates.

RESULTS: The ANALI-score without gadolinium had poor to moderate (ICC = 0.56, 95 %CI: 0.42-0.68) and with gadolinium poor (ICC = 0.30, 95 %CI: 0.16-0.44) agreement. Liver deformity (ICC = 0.28, 95 %CI: 0.13-0.44) and parenchymal enhancement heterogeneity (ICC = 0.24, 95 %CI: 0.12-0.38) had poor agreement. Portal hypertension had poor to moderate (ICC = 0.48, 95 %CI: 0.36-0.59) and dilatation of the intrahepatic ducts had moderate (ICC = 0.64, 95 %CI: 0.54-0.73) agreement. Hazard ratios for liver-related death, transplantation or cirrhosis decompensation of the ANALI-scores with and without gadolinium were 3.53 (95 %CI: 1.40-8.93) and 2.25 (95 %CI: 1.56-3.24), respectively. Outcome-free survival was better for patients with low ANALI-scores.

CONCLUSIONS: The ANALI-scores show poor to moderate agreement, which challenges their usefulness in clinical practice. They are associated with clinical outcomes, confirming the value of imaging in prognosis of PSC, but need further multicenter evaluation.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Grigoriadis A, Ringe KI, Andersson M, et al. Assessment of prognostic value and interreader agreement of ANALI scores in patients with primary sclerosing cholangitis. Eur J Radiol. 2021. PMID: 34380098. doi:10.1016/j.ejrad.2021.109884

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。